Book an appointment with us, or search the directory to find the right lawyer for you directly through the app.
Find out moreThis comprehensive guide is designed to help you navigate the intricate landscape of family business and private wealth in the Middle East, where family businesses constitute approximately 60% of GDP and employ 80% of the workforce in the GCC, offering unparalleled opportunities for wealth creation and preservation.
Packed with insights, strategies, and expert advice from our talented lawyers, Legacy provides tailored solutions to the unique challenges of asset protection, succession planning, and dispute resolution in this dynamic region.Read the publication and equip yourself with the knowledge and tools necessary to thrive, whether you’re a seasoned investor, a family business owner, part of the next generation, or a newcomer exploring opportunities in the region.
Read NowIn October 2023, the Saudi Food and Drug Authority (‘SFDA‘) issued a guidance document on its new breakthrough medicines program (‘BMP’). The BMP aims to facilitate and accelerate development and review of new drugs that address unmet medical need in the treatment of serious or life-threatening conditions.
Under the breakthrough medicine program, the designation request may be submitted by the end of phase 2 trials, or at any time after. All four criteria must be fulfilled in order to gain a breakthrough medicine designation:
As part of the application for designation as a BMP and completion of the Breakthrough Medicine Designation Form, the applicant should submit preliminary evidence, based on non-clinical and clinical data, that the advantage claimed for the product may be of significant relevance to the patient and will address their unmet need. A well-argued evaluation of the likelihood of achievement of the product’s claim should be provided, based on the totality of information available at the time of designation.
Following granting of the BMP designation, an applicant must submit the medicine application file within 30 working days after granting the designation. The application shall be submitted through Saudi Drug Registration (‘SDR‘) System and according to the SFDA’s “Guidance for Submission”. The applicant may request an exemption for one or more of the registration requirements, if unavailable (e.g. CPP, leaflet and artwork). The scientific assessment takes 60 working days. When the SFDA has sufficient information about the product, it will make a decision on whether or not a medicine should be granted a marketing authorisation.
Importantly, the company can start the medication access negotiation process with all involved healthcare entities in parallel with application review.
Al Tamimi & Company’s Healthcare & Life Sciences practice in Saudi Arabia spans all three of our KSA offices (Riyadh, Jeddah, & Al Khobar) and is well placed to advise on regulatory matters impacting the life sciences industry, such as the SFDA Break Through Medicine Program.
To learn more about our services and get the latest legal insights from across the Middle East and North Africa region, click on the link below.